BMY Long
Trade Idea
Enter Long
- Ideal price is $64-$66
Stop Loss
- $64.4
Profit Target
- $70-$71
ARK fund is dumping Bristol-Myers Squibb (BMY), should you?
Yet another solid company with solid financials who is currently trading at 65.6% below estimated fair values. Earnings are forecasted to grow 30.88% per year. This stock also pays out a reliable dividend of 2.96%. Caution as there has been significant insider selling over the past 3 months. I plan on buying this at open tomorrow and holding for a few weeks or until price target is reached.
For the six months ended 30 June 2021, Bristol-Myers Squibb Co revenues increased 9% to 22.78B. Net income totaled 3.08B vs. loss of 860M. Revenues reflect Prioritized Brands-Eliquis segment increase of 18% to5.68B, Prioritized Brands-Revlimid segment increase of 6%to 6.15B, United States segment increase of 9% to 14.4B,Europe segment increase of 11% to 5.24B.
Enter Long
- Ideal price is $64-$66
Stop Loss
- $64.4
Profit Target
- $70-$71
ARK fund is dumping Bristol-Myers Squibb (BMY), should you?
Yet another solid company with solid financials who is currently trading at 65.6% below estimated fair values. Earnings are forecasted to grow 30.88% per year. This stock also pays out a reliable dividend of 2.96%. Caution as there has been significant insider selling over the past 3 months. I plan on buying this at open tomorrow and holding for a few weeks or until price target is reached.
For the six months ended 30 June 2021, Bristol-Myers Squibb Co revenues increased 9% to 22.78B. Net income totaled 3.08B vs. loss of 860M. Revenues reflect Prioritized Brands-Eliquis segment increase of 18% to5.68B, Prioritized Brands-Revlimid segment increase of 6%to 6.15B, United States segment increase of 9% to 14.4B,Europe segment increase of 11% to 5.24B.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.